Bicycle Therapeutics plc (BCYC) Misses Q3 EPS by 7c

Bicycle Therapeutics plc (NASDAQ: BCYC) reported Q3 EPS of ($0.96), $0.07 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $3.04 million versus the consensus estimate of $5.58 million.

For earnings history and earnings-related data on Bicycle Therapeutics plc (BCYC) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94